BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 32422065)

  • 1. Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19).
    Schoergenhofer C; Jilma B; Stimpfl T; Karolyi M; Zoufaly A
    Ann Intern Med; 2020 Oct; 173(8):670-672. PubMed ID: 32422065
    [No Abstract]   [Full Text] [Related]  

  • 2. Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect.
    Stader F; Khoo S; Stoeckle M; Back D; Hirsch HH; Battegay M; Marzolini C
    J Antimicrob Chemother; 2020 Oct; 75(10):3084-3086. PubMed ID: 32556272
    [No Abstract]   [Full Text] [Related]  

  • 3. Lopinavir pharmacokinetics in COVID-19 patients.
    Gregoire M; Le Turnier P; Gaborit BJ; Veyrac G; Lecomte R; Boutoille D; Canet E; Imbert BM; Bellouard R; Raffi F
    J Antimicrob Chemother; 2020 Sep; 75(9):2702-2704. PubMed ID: 32443151
    [No Abstract]   [Full Text] [Related]  

  • 4. Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia.
    Beyls C; Martin N; Hermida A; Abou-Arab O; Mahjoub Y
    Circ Arrhythm Electrophysiol; 2020 Aug; 13(8):e008798. PubMed ID: 32809882
    [No Abstract]   [Full Text] [Related]  

  • 5. [Adverse effects of lopinavir/ritonavir in critically ill patients with COVID-19].
    Vecchio G; Zapico V; Catanzariti A; Carboni Bisso I; Las Heras M
    Medicina (B Aires); 2020; 80(5):439-441. PubMed ID: 33048786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
    Cao B; Wang Y; Wen D; Liu W; Wang J; Fan G; Ruan L; Song B; Cai Y; Wei M; Li X; Xia J; Chen N; Xiang J; Yu T; Bai T; Xie X; Zhang L; Li C; Yuan Y; Chen H; Li H; Huang H; Tu S; Gong F; Liu Y; Wei Y; Dong C; Zhou F; Gu X; Xu J; Liu Z; Zhang Y; Li H; Shang L; Wang K; Li K; Zhou X; Dong X; Qu Z; Lu S; Hu X; Ruan S; Luo S; Wu J; Peng L; Cheng F; Pan L; Zou J; Jia C; Wang J; Liu X; Wang S; Wu X; Ge Q; He J; Zhan H; Qiu F; Guo L; Huang C; Jaki T; Hayden FG; Horby PW; Zhang D; Wang C
    N Engl J Med; 2020 May; 382(19):1787-1799. PubMed ID: 32187464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
    Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug interaction monitoring of lopinavir/ritonavir in COVID-19 patients with cancer].
    Zheng XW; Tao G; Zhang YW; Yang GN; Huang P
    Zhonghua Nei Ke Za Zhi; 2020 May; 59(5):400-404. PubMed ID: 32114746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BET 1: Lopinavir-ritonavir and COVID-19.
    Dolan D; Ingham J; Baombe J
    Emerg Med J; 2020 Jul; 37(7):450-451. PubMed ID: 32616658
    [No Abstract]   [Full Text] [Related]  

  • 11. Ritonavir/Lopinavir and Its Potential Interactions With Psychiatric Medications: A COVID-19 Perspective.
    Mansuri Z; Shah B; Adnan M; Chaudhari G; Jolly T
    Prim Care Companion CNS Disord; 2020 Jun; 22(3):. PubMed ID: 32569450
    [No Abstract]   [Full Text] [Related]  

  • 12. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
    Bhatnagar T; Murhekar MV; Soneja M; Gupta N; Giri S; Wig N; Gangakhedkar R
    Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):184-189. PubMed ID: 32362644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients.
    Lê MP; Jaquet P; Patrier J; Wicky PH; Le Hingrat Q; Veyrier M; Kauv J; Sonneville R; Visseaux B; Laouénan C; Bouadma L; Descamps D; de Montmollin E; Peytavin G; Timsit JF
    J Antimicrob Chemother; 2020 Sep; 75(9):2657-2660. PubMed ID: 32688374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol.
    Zeng YM; Xu XL; He XQ; Tang SQ; Li Y; Huang YQ; Harypursat V; Chen YK
    Chin Med J (Engl); 2020 May; 133(9):1132-1134. PubMed ID: 32149772
    [No Abstract]   [Full Text] [Related]  

  • 15. Adding Colchicine to the Antiretroviral Medication - Lopinavir/Ritonavir (Kaletra) in Hospitalized Patients with Non-Severe Covid-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomized Controlled Trial.
    Dalili N; Kashefizadeh A; Nafar M; Poorrezagholi F; Firouzan A; Samadian F; Samavat S; Ziaie S; Fatemizadeh S
    Trials; 2020 Jun; 21(1):489. PubMed ID: 32503620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Race to find COVID-19 treatments accelerates.
    Kupferschmidt K; Cohen J
    Science; 2020 Mar; 367(6485):1412-1413. PubMed ID: 32217705
    [No Abstract]   [Full Text] [Related]  

  • 17. Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir.
    Mas Serrano M; Pérez-Sánchez JR; Portela Sánchez S; De La Casa-Fages B; Mato Jimeno V; Pérez Tamayo I; Grandas F
    J Neurol Sci; 2020 Aug; 415():116944. PubMed ID: 32531579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Trial of Lopinavir-Ritonavir in Covid-19.
    Carmona-Bayonas A; Jimenez-Fonseca P; Castañón E
    N Engl J Med; 2020 May; 382(21):e68. PubMed ID: 32369285
    [No Abstract]   [Full Text] [Related]  

  • 19. A Trial of Lopinavir-Ritonavir in Covid-19.
    Corrao S; Natoli G; Cacopardo B
    N Engl J Med; 2020 May; 382(21):e68. PubMed ID: 32369284
    [No Abstract]   [Full Text] [Related]  

  • 20. A Trial of Lopinavir-Ritonavir in Covid-19.
    Havlichek D
    N Engl J Med; 2020 May; 382(21):e68. PubMed ID: 32369283
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.